Brief: Tcr² Therapeutics reports Q2 results

TCR2 Therapeutics

08/08/2022 11:50

Aug 8 (Reuters) - TCR2 Therapeutics Inc  TCRR.O :
    * TCR² THERAPEUTICS REPORTS SECOND QUARTER 2022 FINANCIAL
RESULTS
AND PROVIDES CORPORATE UPDATE
    * ENDED Q2 OF 2022 WITH $206.2 MILLION IN CASH, CASH
EQUIVALENTS,
AND INVESTMENTS COMPARED TO $265.6 MILLION AS OF DECEMBER 31,
2021
    * EXPECT CASH ON HAND TO SUPPORT OPERATIONS INTO 2024.
    * QTRLY NET LOSS PER SHARE OF COMMON STOCK, BASIC AND
DILUTED
$0.82
    * Q2 EARNINGS PER SHARE VIEW $-0.79 -- REFINITIV IBES DATA
    * INITIAL TC-510 PHASE 1 DATA ANTICIPATED IN 2H 2022
    * GAVO-CEL PHASE 1 TRIAL DATASET ANTICIPATED IN SEPTEMBER
2022

Source text for Eikon:  ID:nGNX6VpYPn 
Further company coverage:  TCRR.O 

 (Reporting by Priyamvada C)
 ((Priyamvada.C@thomsonreuters.com;))